Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERONICA Trial
NCT04654052Phase 4Completed
- Sponsor
- EPIC Holdings
- Start
- Jul 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of clopidogrel in acute coronary syndrome (ACS) (2 arms), sponsored by EPIC Holdings. Primary endpoint: Net Adverse Cardiac Events at 12 months. Started Jul 2021; status: completed.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04654052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654052.